Core targets as determined in the same manner have also revealed that prostaglandin-endoperoxide synthase 1 (PTGS1), estrogen receptor 1 (ESR1), androgen receptor (AR), peroxisome proliferator-activated receptor γ (PPARG), and thrombomodulin (THBD) were potentially key targets for MDS treatment (Figure 3 and Table 3). Here, ESR1 is linked to myelodysplastic syndrome.